Silvia L. Locatelli

Rozzano, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma.

The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma.

Journal: Anticancer research
Published: November 24, 2021

Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis.

Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis.

Journal: Bone reports
Published: September 30, 2019

Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis.

Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis.

Journal: Haematologica
Published: September 14, 2019

FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.

FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.

Journal: Cancer research
Published: August 29, 2019

A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.

A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: August 27, 2019

MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation.

MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation.

Journal: Haematologica
Published: May 24, 2018

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 16, 2018

Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.

Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.

Journal: Scientific reports
Published: April 04, 2018

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

Journal: Blood
Published: November 03, 2017

The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

Journal: Leukemia
Published: August 09, 2016

Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.

Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.

Journal: Scientific reports
Published: August 01, 2016

Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy.

Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy.

Journal: Oncotarget
Published: June 09, 2016
Showing 1-12 of 21

Last Updated: 09/26/2026